

# Jindřika Gatterová

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2258804/publications.pdf>

Version: 2024-02-01

27  
papers

1,933  
citations

471371

17  
h-index

642610

23  
g-index

27  
all docs

27  
docs citations

27  
times ranked

1878  
citing authors

#	ARTICLE	IF	CITATIONS
1	Glucosamine Sulfate Use and Delay of Progression of Knee Osteoarthritis. Archives of Internal Medicine, 2002, 162, 2113.	4.3	584
2	Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2003, 62, 427-430.	0.5	232
3	Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis and Cartilage, 2002, 10, 707-713.	0.6	156
4	Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis and Cartilage, 2008, 16, 254-260.	0.6	143
5	Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis: Figure 1. Annals of the Rheumatic Diseases, 2009, 68, 295-296.	0.5	112
6	Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause, 2004, 11, 138-143.	0.8	104
7	Hyaluronic acid levels may have predictive value for the progression of knee osteoarthritis. Osteoarthritis and Cartilage, 2004, 12, 277-283.	0.6	89
8	Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis and Cartilage, 2001, 9, 612-618.	0.6	80
9	Increased pentosidine, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein. Annals of the Rheumatic Diseases, 2005, 64, 886-890.	0.5	67
10	A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon®) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthritis and Cartilage, 2000, 8, 335-342.	0.6	63
11	Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis. Annals of the Rheumatic Diseases, 2012, 71, 71-74.	0.5	55
12	RANTES, MCP-1 chemokines and factors describing rheumatoid arthritis. Molecular Immunology, 2012, 52, 273-278.	1.0	52
13	Polymorphism in the tumor necrosis factor-Î± gene promoter is associated with severity of rheumatoid arthritis in the Czech population. Clinical Rheumatology, 2007, 27, 59-65.	1.0	39
14	Serum hyaluronic acid as a potential marker with a predictive value for further radiographic progression of hand osteoarthritis. Osteoarthritis and Cartilage, 2009, 17, 1615-1619.	0.6	39
15	Seronegative Lyme Arthritis caused by Borrelia garinii. Clinical Rheumatology, 2002, 21, 330-334.	1.0	31
16	Glycosaminoglycan polysulfuric acid (GAGPS) in osteoarthritis of the knee. Osteoarthritis and Cartilage, 1995, 3, 15-23.	0.6	22
17	Relation of IL-6, IL-13 and IL-15 gene polymorphisms to the rheumatoid factors, anti-CCP and other measures of rheumatoid arthritis activity. International Journal of Immunogenetics, 2014, 41, 34-40.	0.8	18
18	Association of the 5A/6A Promoter Polymorphism of the MMP-3 Gene with the Radiographic Progression of Rheumatoid Arthritis. Annals of the New York Academy of Sciences, 2007, 1110, 166-176.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Association of the -1082 G/A promoter polymorphism of interleukin-10 gene with the autoantibodies production in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2009, 28, 899-905.	1.0	11
20	Circulating cytokine pattern and factors describing rheumatoid arthritis: IL-15 as one of the biomarkers for RA?. <i>Biomarkers</i> , 2012, 17, 655-662.	0.9	9
21	Association of Polymorphisms in Interleukin-10 Gene Promoter with Autoantibody Production in Patients with Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 501-508.	1.8	7
22	Pentosidine, an Advanced Glycation End-Product, May Reflect Clinical and Morphological Features of Hand Osteoarthritis. <i>Open Rheumatology Journal</i> , 2012, 6, 64-69.	0.1	6
23	Enthesopathy of the hip joint. <i>Clinical Rheumatology</i> , 1985, 4, 150-154.	1.0	3
24	AB0708...Differences in Localization and Activity of the Enthesal Involvement between Non-Radiographic and Radiographic Axial Spondyloarthritis by the Ultrasound Assessment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1038.2-1038.	0.5	0
25	FRI0544...Impact of Education in Musculoskeletal Ultrasonography: Good To Excellent Reliability Results in Modified US7 Scoring System after One Year of Continuing Education since Basic or Intermediate Level of Training. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 637.1-637.	0.5	0
26	AB0696...Clinical Characteristics of Spondyloarthritis in The Czech Republic: A Single Centre Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1142.2-1143.	0.5	0
27	Atypical Course of Rheumatoid Arthritis. , 2014, , 65-74.		0